This is your go-to spot for the latest achievements in the life sciences and high-tech startups sphere. Here, we shine a light on the trailblazers and innovators who’ve journeyed through Connect’s Springboard Program. Dive in to discover the groundbreaking milestones of the companies at the forefront of shaping our future.

Carlsmed – a leading medical device company which combines a patented device with patient-
specific data to develop personalized spine surgery care for optimal outcomes. The company
recently announced a favorable reimbursement decision by the Centers for Medicare & Medicaid
Services (CMS). The decision goes into effect October 1, 2024. (Highlighted April 2024)

Cortechs.ai – founded in 1998, Cortechs is a leader in developing brain image analysis software
solutions for several neurological disorders. The company recently received 510(k) clearance from
the Food & Drug Administration (FDA) for their groundbreaking NeuroQuant ® 5.0 software, an AI-
powered image analysis and evaluation system.

FormAlloy Technologies – founded in 2016, FormAlloy is a pioneer in developing Directed Energy
Deposition (DED) systems for 3D metal printing technologies. The company recently celebrated the
grand opening of their new additive manufacturing center in Spring Valley.

HAI Solutions – founded in 2015, HAI Solutions is a medical device company developing innovative
solutions to reducing contamination of IV devices in various hospital settings, thereby reducing
patient infections and saving lives. The company recently participated in the inaugural RM8 iNov8
Pitch Competition held at the annual conference of the American Association of Nurse
Anesthesiology (AANA) Congress. HAI Solutions won the pitch competition, which came with a
$15K prize.

Intraratio – is an innovator in developing enterprise software solutions to automate and streamline
manufacturing operations in the semiconductor, electronics and MEMs industry sectors. For the
second year in a row, the company was awarded the 2024 Mexico Technology Award (MTA) in the
MES software category. The MTA program recognizes companies with new innovations which are
produced by OEM manufacturing equipment and materials suppliers over the last 12 months and
which are available in Mexico. (Highlighted December 2023)

Molecular Assemblies – a pioneering leader in developing DNA synthesis technologies, the company
previously received funding to participate in a new program called NOW (Nucleic Acids On-Demand
Worldwide), which is part of the Defense Advanced Research Projects Agency (DARPA). As a result
of achieving significant milestones, Molecular Assemblies’ participation has been extended and they
were recently awarded an additional $4M to continue further technology development in the next
phase of this DARPA-funded program. (Highlighted June 2024)

NeuraLace Medical – has developed a non-invasive and non-addictive pain reduction medical device
– Axon® Therapy – which was approved by the Food and Drug Administration (FDA) in 2021. They
recently received funding from local angel investment group, NuFund Venture Group. (Highlighted February 2024)

Origami Therapeutics– a pre-clinical stage company developing novel therapeutics to treat
neurodegenerative diseases such as Huntington’s Disease, the company recently received funding
from local angel investment group, NuFund Venture Group. (Highlighted August 2024)

Palm Therapeutics – an early-stage biotechnology company developing proprietary palmitoylation
technology to develop anti-cancer drugs, the company was one of four local startups recently
awarded a Catalyst Grant by San Diego-based Curebound. Curebound is a philanthropic
organization which invests in innovative cancer research. (Highlighted March 2024)

Papillon Therapeutics – is a clinical stage biotech company developing a pipeline of gene therapy
treatments for neurological conditions. The company was recently granted two orphan drug
designations by the U.S. Food and Drug Administration (FDA): one for PPL-001, their experimental
treatment for Friedreich’s ataxia; and the second one for PPL-002, for the treatment of Danon
Disease. (Highlighted May 2024)

Resolute Science– a pre-clinical biotech company whose mission is to develop pan-cancer
therapeutics to treat aggressive and hard-to-treat solid tumors, the company was one of four local
startups recently awarded a Catalyst Grant by San Diego-based Curebound. Curebound is a
philanthropic organization which invests in innovative cancer research. (Highlighted August 2024)

And drum roll … Congratulations to the following companies which we have worked with via our
Springboard program and which are among the recipients of the first investments made by the TL
Fund, a regional accelerator investment fund; each company received $100,000.
Papillon Therapeutics – is developing gene therapy treatments for neurological conditions
Resolute Science – is developing cancer therapeutics for aggressive solid tumors